Skip to main content
Top
Published in: Arthritis Research & Therapy 5/2006

01-10-2006 | Commentary

Safety concerns on the development of novel therapeutic drugs

Authors: Caroline Ospelt, Steffen Gay

Published in: Arthritis Research & Therapy | Issue 5/2006

Login to get access

Abstract

Along with recent innovative approaches resulting in the development of new therapies such as small molecular inhibitors, therapeutic antibodies, recombinant proteins and gene therapy, there is increasing need for improved understanding of the basic molecular mechanisms that are exploited by such treatments. Helpful tools in the analysis of drug effects include high-throughput screening techniques such as microarrays, which are used in transcriptomics and pharmacogenomics. Although we are far from using these extensive and costly tests in our daily clinical routine, their application in basic research nevertheless takes us closer to individualized therapeutic strategies, in which the optimal therapeutic regimen is identified for each individual patient.
Literature
1.
go back to reference Feldmann M, Brennan FM, Williams RO, Woody JN, Maini RN: The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2004, 18: 59-80. 10.1016/j.berh.2003.09.010.CrossRefPubMed Feldmann M, Brennan FM, Williams RO, Woody JN, Maini RN: The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2004, 18: 59-80. 10.1016/j.berh.2003.09.010.CrossRefPubMed
2.
go back to reference Ospelt C, Neidhart M, Gay RE, Gay S: Gene analysis for exploring the effects of drugs in rheumatoid arthritis. Arthritis Rheum. 2005, 52: 2248-2256. 10.1002/art.21196.CrossRefPubMed Ospelt C, Neidhart M, Gay RE, Gay S: Gene analysis for exploring the effects of drugs in rheumatoid arthritis. Arthritis Rheum. 2005, 52: 2248-2256. 10.1002/art.21196.CrossRefPubMed
3.
go back to reference Haupl T, Krenn V, Stuhlmuller B, Radbruch A, Burmester GR: Perspectives and limitations of gene expression profiling in rheumatology: new molecular strategies. Arthritis Res Ther. 2004, 6: 140-146. 10.1186/ar1194.PubMedCentralCrossRefPubMed Haupl T, Krenn V, Stuhlmuller B, Radbruch A, Burmester GR: Perspectives and limitations of gene expression profiling in rheumatology: new molecular strategies. Arthritis Res Ther. 2004, 6: 140-146. 10.1186/ar1194.PubMedCentralCrossRefPubMed
4.
go back to reference Jarvis JN, Dozmorov I, Jiang K, Frank MB, Szodoray P, Alex P, Centola M: Novel approaches to gene expression analysis of active polyarticular juvenile rheumatoid arthritis. Arthritis Res Ther. 2004, 6: R15-R32. 10.1186/ar1018.PubMedCentralCrossRefPubMed Jarvis JN, Dozmorov I, Jiang K, Frank MB, Szodoray P, Alex P, Centola M: Novel approaches to gene expression analysis of active polyarticular juvenile rheumatoid arthritis. Arthritis Res Ther. 2004, 6: R15-R32. 10.1186/ar1018.PubMedCentralCrossRefPubMed
5.
go back to reference Deng MC, Eisen HJ, Mehra MR, Billingham M, Marboe CC, Berry G, Kobashigawa J, Johnson FL, Starling RC, Murali S, et al: Non-invasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant. 2006, 6: 150-160. 10.1111/j.1600-6143.2005.01175.x.CrossRefPubMed Deng MC, Eisen HJ, Mehra MR, Billingham M, Marboe CC, Berry G, Kobashigawa J, Johnson FL, Starling RC, Murali S, et al: Non-invasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant. 2006, 6: 150-160. 10.1111/j.1600-6143.2005.01175.x.CrossRefPubMed
6.
go back to reference Hopkin M: Can super-antibody drugs be tamed?. Nature. 2006, 440: 855-856. Hopkin M: Can super-antibody drugs be tamed?. Nature. 2006, 440: 855-856.
7.
go back to reference Thomsen M, Yacoub-Youssef H, Marcheix B: Reconstitution ofa human immune system in immunodeficient mice: models of humanalloreaction in vivo. Tissue Antigens. 2005, 66: 73-82. 10.1111/j.1399-0039.2005.00409.x.CrossRefPubMed Thomsen M, Yacoub-Youssef H, Marcheix B: Reconstitution ofa human immune system in immunodeficient mice: models of humanalloreaction in vivo. Tissue Antigens. 2005, 66: 73-82. 10.1111/j.1399-0039.2005.00409.x.CrossRefPubMed
8.
go back to reference Ranganathan P, McLeod HL: Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum. 2006, 54: 1366-1377. 10.1002/art.21762.CrossRefPubMed Ranganathan P, McLeod HL: Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum. 2006, 54: 1366-1377. 10.1002/art.21762.CrossRefPubMed
9.
go back to reference Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D: Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum. 2005, 52: 2693-2696. 10.1002/art.21266.CrossRefPubMed Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D: Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum. 2005, 52: 2693-2696. 10.1002/art.21266.CrossRefPubMed
10.
go back to reference Schotte H, Schluter B, Drynda S, Willeke P, Tidow N, Assmann G, Domschke W, Kekow J, Gaubitz M: Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. Ann Rheum Dis. 2005, 64: 575-581. 10.1136/ard.2004.027672.PubMedCentralCrossRefPubMed Schotte H, Schluter B, Drynda S, Willeke P, Tidow N, Assmann G, Domschke W, Kekow J, Gaubitz M: Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. Ann Rheum Dis. 2005, 64: 575-581. 10.1136/ard.2004.027672.PubMedCentralCrossRefPubMed
11.
go back to reference Fabris M, Tolusso B, Di Poi E, Assaloni R, Sinigaglia L, Ferraccioli G: Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. J Rheumatol. 2002, 29: 1847-1850.PubMed Fabris M, Tolusso B, Di Poi E, Assaloni R, Sinigaglia L, Ferraccioli G: Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. J Rheumatol. 2002, 29: 1847-1850.PubMed
12.
go back to reference Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D: Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum. 2003, 48: 1849-1852. 10.1002/art.11168.CrossRefPubMed Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D: Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum. 2003, 48: 1849-1852. 10.1002/art.11168.CrossRefPubMed
Metadata
Title
Safety concerns on the development of novel therapeutic drugs
Authors
Caroline Ospelt
Steffen Gay
Publication date
01-10-2006
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 5/2006
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2032

Other articles of this Issue 5/2006

Arthritis Research & Therapy 5/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine